Editorial
The Role of Sulforaphane on Duchenne Muscular Dystrophy by Activation of Nrf2
Cheng-Cao Sun1#, Jing-Yu Pan1#, Shu-Jun Li1,2 and De-Jia Li1*
1Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, P.R. China
2Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, 430071 Wuhan, P.R. China
#Cheng-Cao Sun and Jing-Yu Pan contribute equal to this work
- *Corresponding Author:
- De-Jia Li
Department of Occupational and Environmental Health
School of Public Health, Wuhan University
No.115 Donghu Road, Wuchang District, Wuhan, P. R China
Tel: (86)18271470520
Fax: (86)02768778695
E-mail: lodjlwhu@sina.com
Received Date: August 09, 2015; Accepted Date: August 15, 2015; Published Date: August 20, 2015
Citation: Santini A, Raiola A, Meca G, Ritieni A (2015) The Role of Sulforaphane on Duchenne Muscular Dystrophy by Activation of Nrf2. Interdiscip J Microinflammation 3:e104. doi: 10.4172/2381-8727.1000e104
Copyright: © 2015 De-Jia Li, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Sulforaphane (SFN) possesses powerful chemo-preventive effects and plays a crucial role on oxidative stress and inflammatory. In our recent study, SFN treatment could relieve muscular dystrophy in mdx mice by activating Nrf2 (NF-E2 related factor 2). Moreover, our findings indicated that SFN-activated Nrf2 alleviated muscle inflammation in dystrophin-deficient mdx mice through suppressing NF-κB signaling pathway. Collectively, SFNinduced Nrf2 molecular pathway might be a promising approach for treatment of the patients with Duchenne muscular dystrophy.
